Our study suggests that EA may be considered as a new insulin sensitizer, which may control the epidemics of obesity and T2DM in parallel, to provide longer, healthier lives to people diagnosed with T2DM and to those who are at risk for developing this disease in the future. This evidence concerns the gene INS and type 2 diabetes mellitus.